DSpace Repository

Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv

Show simple item record

dc.contributor.author Mugweru, Julius
dc.contributor.author Liu, Jianxiong
dc.contributor.author Makafe, Gaelle
dc.contributor.author Chiwala, Gift
dc.contributor.author Wang, Bangxing
dc.contributor.author Wang, Changwei
dc.contributor.author Li, Xinjie
dc.contributor.author Tan, Yaoju
dc.contributor.author Yew, Wing Wai
dc.contributor.author Tan, Shouyong
dc.contributor.author Zhang, Tianyu
dc.date.accessioned 2018-06-13T12:57:03Z
dc.date.available 2018-06-13T12:57:03Z
dc.date.issued 2018-06
dc.identifier.citation Infection and Drug Resistance 2018:11 891–894 en_US
dc.identifier.uri http://hdl.handle.net/123456789/1527
dc.description.abstract Ethionamide (ETA) and prothionamide (PRO) are interchangeably used in tuberculosis (TB) chemotherapy regimens. Subtle discrepancies between biochemical and genetic information on the modes of sensitivity and resistance of isoniazid (INH) and ETA warrants further studies. We report a new mutation – EthAW21R – in Mycobacterium bovis Bacillus Calmette-Guérin that corresponds with co-resistance to both PRO and ETA, which to the best of our knowledge has not been reported before. Our findings suggest that mutation EthAW21R could be used as a marker site for testing PRO and ETA cross-resistance en_US
dc.language.iso en en_US
dc.publisher Dove Press en_US
dc.subject mutation en_US
dc.subject EthAW21R en_US
dc.subject isoniazid en_US
dc.subject co-resistance en_US
dc.subject thioamides en_US
dc.subject molecular marker en_US
dc.title Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account